The Patent Finder

ANTI-CD3 Antibodies and Methods of Use

Genentech, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 7 of these applications claim priority to application 62/091,441, filed Dec 12, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 10,865,251ANTI-CD3 Antibodies and Methods of Use
In force
 · High confidence
Genentech, Inc.In force
High confidence
US 11,186,650ANTI-CD3 Antibodies and Methods of Use
In force
 · Medium confidence
Genentech, Inc.In force
Medium confidence
US 10,640,572ANTI-CD3 Antibodies and Methods of Use
In force
 · High confidence
Genentech, Inc.In force
High confidence
US 11,530,275ANTI-CD3 Antibodies and Methods of Use
In force
 · Medium confidence
Genentech, Inc.In force
Medium confidence
US 12,466,896ANTI-CD3 Antibodies and Methods of Use
In force
 · High confidence
Genentech, IncIn force
High confidence
US 11,732,054ANTI-CD3 Antibodies and Methods of Use
In force
 · High confidence
Genentech, Inc.In force
High confidence
US 10,174,124ANTI-CD3 Antibodies and Methods of Use
In force
 · High confidence
Genentech, Inc.In force
High confidence
Application 19/337,201ANTI-CD3 Antibodies and Methods of Use
Abandoned
Abandoned Jun 4, 2026
Genentech, Inc.AbandonedAbandoned Jun 4, 2026
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
7 of these are in force and held by Genentech, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited